Keshen Aaron, Helson Thomas
Eating Disorder Program, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
J Clin Pharmacol. 2017 Jul;57(7):818-822. doi: 10.1002/jcph.868. Epub 2017 Jan 23.
Psychostimulants have been assessed in bulimia nervosa patients with comorbid attention deficit/hyperactivity disorder (ADHD), but few studies have examined the impact of psychostimulants on bulimia nervosa patients without comorbid ADHD. The aim of this study was to examine psychostimulants as a potential treatment for bulimia nervosa and to assess the concern of weight loss, given the medication's appetite-suppressing effects. This retrospective study describes 6 case reports of outpatients who were prescribed a psychostimulant specifically for their bulimia nervosa. The number of binge/purge days per months and body mass index were assessed. All patients demonstrated reductions in the number of binge/purge days per month, and 1 patient experienced total remission of bulimic symptoms. Minor fluctuations in weight were observed, but no clinically significant reductions in weight were noted. These findings support the need for clinical trials to examine the efficacy and safety of this potential treatment.
精神兴奋剂已在患有注意力缺陷/多动障碍（ADHD）合并症的神经性贪食症患者中进行了评估，但很少有研究考察精神兴奋剂对无ADHD合并症的神经性贪食症患者的影响。本研究的目的是考察精神兴奋剂作为神经性贪食症的一种潜在治疗方法，并鉴于该药物的食欲抑制作用，评估对体重减轻的担忧。这项回顾性研究描述了6例专门因神经性贪食症而开具精神兴奋剂的门诊患者的病例报告。评估了每月的暴饮暴食/清除天数和体重指数。所有患者每月的暴饮暴食/清除天数均有所减少，1例患者的贪食症状完全缓解。观察到体重有轻微波动，但未发现临床上有显著的体重减轻。这些发现支持需要进行临床试验来检验这种潜在治疗方法的疗效和安全性。
